DaVita Inc.
DaVita Inc. Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management said on revenue, margins and capex.
What the Q2 FY26 call signalled
1 of 3 strong
The short version
- Treatment volume guidance raised from flat to 25-50 basis points growth for 2026, driven by better underlying performance and patient transfers from Fresenius clinic closures. - DaVita raised its 2026 adjusted operating income guidance to a range of $2.15 billion to $2.25 billion, driven primarily by higher treatment volume and lower patient care costs.
From DaVita Inc.'s Q2 FY26 earnings-call transcript · updated 30 May 2026.
Revenue & Sales Performance
- Treatment volume guidance raised from flat to 25-50 basis points growth for 2026, driven by better underlying performance and patient transfers from Fresenius clinic closures.
- Treatments per normalized day expected to grow 50-75 basis points in 2026.
- Revenue per treatment (RPT) growth forecast remains 1% to 2% for the full year despite Q1 being about 4% higher due to timing effects.
- Commercial mix is expected to decline over the year, potentially pressuring RPT.
2 more points from DaVita Inc.'s call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what DaVita Inc. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- DaVita is making targeted technology investments to expand their IT systems and digital infrastructure, empowering clinical teams and supporting future clinical and operational excellence.
- Continued investment in AI solutions and data infrastructure modernization, including their proprietary EMR platform, to enhance clinical, operational, and business use cases.
- Example given: deployment of ScheduleHub, a tool for optimizing patient and staffing schedules in real time, aiming to reduce administrative burden and improve teammate experience.
- These tech investments are reflected in a 13% increase in G&A costs year-over-year due to sustained IT investment.
2 more points from DaVita Inc.'s call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what DaVita Inc. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what DaVita Inc. said on order book & pipeline — free account, 30 seconds.
Continue your research
Others in Health Care Providers and Services this season
- BrightSpring Health Services, Inc. (Q2 FY26)
BrightSpring Health Services, Inc. Q2 FY26 quarterly results analysis. Pharmacy Solutions expected to see balanced sequential revenue and EBITDA growth througho
- Tenet Healthcare Corporation (Q2 FY26)
Tenet Healthcare Corporation Q2 FY26 quarterly results analysis. Hospital segment expects a 10% normalized year-over-year adjusted EBITDA growth in 2026, suppor
- Guardant Health, Inc. (Q2 FY26)
Guardant Health, Inc. Q2 FY26 quarterly results analysis. Sales team started this year with ~300 reps; incremental gross profit will be reinvested in expanding
- Quest Diagnostics Incorporated (Q2 FY26)
Quest Diagnostics Incorporated Q2 FY26 quarterly results analysis. Q1 2026 organic volume growth was strong at 10.8%, with total volume growth at 10.9%. Market
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
DaVita Inc. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were DaVita Inc. Q2 FY26 results?
- Treatment volume guidance raised from flat to 25-50 basis points growth for 2026, driven by better underlying performance and patient transfers from Fresenius clinic closures. - DaVita raised its 2026 adjusted operating income guidance to a range of $2.15 billion to $2.25 billion, driven primarily by higher treatment volume and lower patient care costs.
What is DaVita Inc. share price analysis?
DaVita Inc. currently shows a neutral. The stock trades at a P/E of 18.8 with a market cap of $12,654. Investors should review the full earnings analysis for detailed insights.
Is DaVita Inc. planning capital expenditure?
- DaVita is making targeted technology investments to expand their IT systems and digital infrastructure, empowering clinical teams and supporting future clinical and operational excellence.
Keep DaVita Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.